| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1731653 | Antiproliferative activity against human Jurkat cells assessed as cell survival at 10 uM (Rvb = 104.3 +/ 10.2 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization. |
| AID449971 | Cytotoxicity against mouse L1210 cells after 48 hrs by XTT assay | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
| Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. |
| AID1700010 | Cytotoxicity against human HCT-116 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID677620 | Antitrypanosomal activity against bloodstream form of Trypanosoma brucei 427 after 48 hrs by MTS assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| Identification of selective tubulin inhibitors as potential anti-trypanosomal agents. |
| AID1267184 | Aqueous solubility of the compound by UV-HPLC | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1700012 | Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1432113 | Growth inhibition of human PC3 cells after 48 hrs by MTT assay | | | |
| AID1432155 | Induction of apoptosis in human DU145 cells assessed as upregulation of Bax protein expression at 400 nM after 48 hrs by Western blot method | | | |
| AID1267188 | Solubility in 2% DMSO containing 50 mM potassium phosphate buffer solution pH 7.4 at 1 uM by dynamic light scattering method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID116620 | Percent increase in life span of P388-inoculated leukemic mice at a dose of 200 mg/kg | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1267202 | Cytotoxicity against multidrug resistant human MES-SA/Dx5 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1700009 | Cytotoxicity against human A549 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1700006 | Induction of microtubule destabilization in sea urchin embryo assessed as embryo spinning measured after 0.5 to 20 hrs | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1267217 | Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1700005 | Antimitotic activity against sea urchin embryo assessed as cleavage arrest measured 2.5 to 6 hrs post-fertilization by light microscopy analysis | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1700004 | Antimitotic activity against sea urchin embryo assessed as cleavage alteration measured 2.5 to 6 hrs post-fertilization by light microscopy analysis | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1507098 | Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell survival after 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | |
| AID677621 | Growth inhibition of human SKBR3 cells after 48 hrs by MTT assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| Identification of selective tubulin inhibitors as potential anti-trypanosomal agents. |
| AID1700014 | Cytotoxicity against human DU-145 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID116621 | Percent increase in life span of P388-inoculated leukemic mice at a dose of 25 mg/kg | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID106338 | In vitro anticancer activity against human uterus MES-SA/DX5 subline (doxorubicin-resistant) | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1432138 | Induction of apoptosis in human DU145 cells assessed as early apoptotic cells at 400 nM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.81%) | | | |
| AID1700016 | Cytotoxicity against human HFF cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID431417 | Antiproliferative activity against human HT-29 cells | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies. |
| AID1700031 | Aggregation property of the compound in water | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1507097 | Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | |
| AID1267218 | Cytotoxicity against human MES-SA cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID116619 | Percent increase in life span of P388-inoculated leukemic mice at a dose of 100 mg/kg | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1731655 | Antiproliferative activity against human SMS-SB cells assessed as cell survival at 10 uM (Rvb = 100 +/ 6 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization. |
| AID1700011 | Cytotoxicity against human A-375 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1267190 | Cytotoxicity against human FADU cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID449970 | Cytotoxicity against human KB/HeLa cells after 48 hrs by XTT assay | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
| Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. |
| AID1700013 | Cytotoxicity against human PC-3 cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID1267216 | Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1672883 | Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay | 2019 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
| Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization. |
| AID86572 | In vitro anticancer activity against human hepatocellular HepG2 cells | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1432112 | Growth inhibition of human DU145 cells after 48 hrs by MTT assay | | | |
| AID1432152 | Inhibition of porcine brain tubulin polymerization measured for 1 hr by fluorescence assay | | | |
| AID1432150 | Inhibition of porcine brain tubulin polymerization at 0.5 uM measured for 1 hr by fluorescence assay relative to control | | | |
| AID1267215 | Cytotoxicity against human SCC4 cells assessed as reduction in cell viability after 72 hrs by MTT assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID431418 | Antiproliferative activity against human MDA-MB-231 cells | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies. |
| AID1545776 | Inhibition of bovine brain tubulin polymerization incubated for 1 hr | 2019 | European journal of medicinal chemistry, Dec-01, Volume: 183 | Indole: A privileged scaffold for the design of anti-cancer agents. |
| AID449972 | Cytotoxicity against human SKOV3 cells after 48 hrs by XTT assay | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
| Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. |
| AID1731652 | Antiproliferative activity against human U-937 cells assessed as cell survival at 10 uM (Rvb = 100 +/ 8.7 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization. |
| AID106328 | In vitro anticancer activity against human uterus MES-SA cells | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1267189 | Solubility in 2% DMSO containing 50 mM potassium phosphate buffer solution pH 7.4 at 10 uM by dynamic light scattering method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID88806 | In vitro anticancer activity against human gastric NUGC3 cells | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1267182 | Inhibition of porcine brain tubulin polymerization assessed as reduction in GTP-induced microtubule assembly after 60 mins by OD340 method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1432139 | Induction of apoptosis in human DU145 cells assessed as late apoptotic cells at 400 nM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.55%) | | | |
| AID1646361 | Antiproliferative activity against human HeLa cells assessed as reduction in cell viability | 2020 | Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2
| Design, synthesis and biological evaluation of novel indole-based oxalamide and aminoacetamide derivatives as tubulin polymerization inhibitors. |
| AID324961 | Cytotoxicity against human HL60/TX1000 cells after 72 hrs by MTT assay | 2008 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 18, Issue:6
| Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines. |
| AID1432140 | Induction of apoptosis in human DU145 cells assessed as necrotic cells at 400 nM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.75%) | | | |
| AID1267180 | Inhibition of porcine brain tubulin polymerization after 60 mins by DAPI staining based fluorescence method | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
| An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer. |
| AID1731654 | Antiproliferative activity against human BT-474 cells assessed as cell survival at 10 uM (Rvb = 100 +/ 6.3 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Indolyl-α-keto-1,3,4-oxadiazoles: Synthesis, anti-cell proliferation activity, and inhibition of tubulin polymerization. |
| AID1432137 | Induction of apoptosis in human DU145 cells assessed as live cells at 400 nM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 95.89%) | | | |
| AID103746 | In vitro anticancer activity against human breast MCF-7 cells | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID26229 | Calculated partition coefficient (clogP) (AlogP) | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID152705 | In vitro anticancer activity against murine leukemic P388 cells | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1432115 | Growth inhibition of human HCT15 cells after 48 hrs by MTT assay | | | |
| AID449973 | Cell cycle arrest in human KB/HeLa cells assessed as accumulation in G2/M phase by cytometric analysis | 2009 | Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
| Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. |
| AID1672882 | Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay | 2019 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13
| Resistance mechanisms and cross-resistance for a pyridine-pyrimidine amide inhibitor of microtubule polymerization. |
| AID1700015 | Cytotoxicity against human T47D cells assessed as cell growth inhibition | 2020 | Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23
| Synthesis and biological evaluation of indolylglyoxylamide bisphosphonates, antimitotic microtubule-targeting derivatives of indibulin with improved aqueous solubility. |
| AID103929 | In vitro anticancer activity against human breast MCF-7/ADR subline (adriamycin-resistant) | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID431416 | Inhibition of bovine brain tubulin polymerization | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
| Indolobenzazepin-7-ones and 6-, 8-, and 9-membered ring derivatives as tubulin polymerization inhibitors: synthesis and structure--activity relationship studies. |
| AID1432114 | Growth inhibition of human A549 cells after 48 hrs by MTT assay | | | |
| AID116622 | Percent increase in life span of P388-inoculated leukemic mice at a dose of 50 mg/kg | 2003 | Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
| Synthesis and biological evaluation of N-heterocyclic indolyl glyoxylamides as orally active anticancer agents. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |